Publications by authors named "Keigo Matsunaga"
Background: Many studies have reported a correlation between lymph node metastasis and prognosis in patients with colorectal cancer. However, the clinical significance of enlarged lymph nodes for prognosis has scarcely been explored.
Objective: This study aimed to assess the clinical significance of enlarged lymph nodes in stage II colorectal cancer.
The genetic risk factors for anastomotic recurrence (AR) after curative surgery for colorectal cancer (CRC) are unclear. The present study is a single-center retrospective observational study that aimed to elucidate the association between the mutation and AR in CRC. The present study included 21 patients with AR and 67 patients with non-anastomotic local recurrence (NALR) following curative surgery for CRC between January 2005 and December 2019.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates the risk factors for anastomotic recurrence in colorectal cancer and compares its prognosis with nonanastomatic local recurrence, using data from 1,584 patients who underwent surgery from 2005 to 2017.
- Results show that anastomotic recurrence occurred in 0.95% of patients, with risk factors being lymph node metastasis and advanced T stage, but prognosis was similar to nonanastomotic cases.
- Limitations include the small sample size of patients with anastomotic recurrence and potential biases due to the study's retrospective nature.
Background/aims: Runt-related transcription factor (RUNX) 3 is a tumor suppressor whose expression is reduced in non-neoplastic rectal mucosa of patients with ulcerative colitis (UC) with coexisting colitis-associated cancer (CAC). We aimed to evaluate RUNX3 utility as a predictive marker for CAC using immunohistochemistry (IHC) for non-neoplastic UC mucosa.
Methods: We retrospectively compared the RUNX3 expression detected by IHC between non-neoplastic rectal biopsy specimens from 20 cases with invasive cancer (CAC group) and 20 cases selected from 138 patients without CAC (non-CAC group) that were treated during the same period (2006-2017) and were matched for sex, duration, extension, and age.